These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19089820)

  • 1. Application of molecular connectivity and electro-topological indices in quantitative structure-activity analysis of pyrazole derivatives as inhibitors of factor Xa and thrombin.
    Krishnasamy C; Raghuraman A; Kier LB; Desai UR
    Chem Biodivers; 2008 Dec; 5(12):2609-20. PubMed ID: 19089820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
    J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are factor Xa inhibitors superior to thrombin inhibitors in anticoagulation?
    Stürzebecher J; Stürzebecher U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):152-6. PubMed ID: 2459011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
    Varnes JG; Wacker DA; Pinto DJ; Orwat MJ; Theroff JP; Wells B; Galemo RA; Luettgen JM; Knabb RM; Bai S; He K; Lam PY; Wexler RR
    Bioorg Med Chem Lett; 2008 Jan; 18(2):749-54. PubMed ID: 18054227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
    Pruitt JR; Pinto DJ; Galemmo RA; Alexander RS; Rossi KA; Wells BL; Drummond S; Bostrom LL; Burdick D; Bruckner R; Chen H; Smallwood A; Wong PC; Wright MR; Bai S; Luettgen JM; Knabb RM; Lam PY; Wexler RR
    J Med Chem; 2003 Dec; 46(25):5298-315. PubMed ID: 14640539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa.
    Frédérick R; Robert S; Charlier C; de Ruyck J; Wouters J; Pirotte B; Masereel B; Pochet L
    J Med Chem; 2005 Dec; 48(24):7592-603. PubMed ID: 16302799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GAGs-potentiated inhibition of thrombin, factor Xa and plasmin in plasma and in a purified system containing antithrombin III - correlation with total charge density.
    Cofrancesco E; Vigo A; Pogliani EM
    Thromb Haemost; 1981 Dec; 46(4):749-51. PubMed ID: 6460339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative structure activity relationship studies of aryl heterocycle-based thrombin inhibitors.
    Deswal S; Roy N
    Eur J Med Chem; 2006 Nov; 41(11):1339-46. PubMed ID: 16884829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective and dual action orally active inhibitors of thrombin and factor Xa.
    Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
    Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heuristic molecular lipophilicity potential (HMLP): a 2D-QSAR study to LADH of molecular family pyrazole and derivatives.
    Du Q; Mezey PG; Chou KC
    J Comput Chem; 2005 Apr; 26(5):461-70. PubMed ID: 15690416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
    Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
    J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
    J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
    Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring QSAR for substituted 2-sulfonyl-phenyl-indol derivatives as potent and selective COX-2 inhibitors using different chemometrics tools.
    Khoshneviszadeh M; Edraki N; Miri R; Hemmateenejad B
    Chem Biol Drug Des; 2008 Dec; 72(6):564-74. PubMed ID: 19090923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to selective peptidic inhibitors of factor Xa.
    Bromfield KM; Quinsey NS; Duggan PJ; Pike RN
    Chem Biol Drug Des; 2006 Jul; 68(1):11-9. PubMed ID: 16923021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fuzzy tricentric pharmacophore fingerprints. 2. Application of topological fuzzy pharmacophore triplets in quantitative structure-activity relationships.
    Bonachéra F; Horvath D
    J Chem Inf Model; 2008 Feb; 48(2):409-25. PubMed ID: 18254617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
    Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism-based thrombin inhibitors: design, synthesis, and molecular docking of a new selective 2-oxo-2H-1-benzopyran derivative.
    Frédérick R; Robert S; Charlier C; Wouters J; Masereel B; Pochet L
    J Med Chem; 2007 Jul; 50(15):3645-50. PubMed ID: 17580844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.